Skip to main content
Clinical Trials/CTRI/2024/01/061165
CTRI/2024/01/061165
Not yet recruiting
未知

A prospective, Single-Centre study to investigate the plaque characteristics in the culprit vessels in young Indian patients (=18 - =40 yrs) with ACS undergoing PCI by Optical Coherence Tomography imaging. - YPS40

Dr Nityanand Tripathi0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: I248- Other forms of acute ischemic heart disease
Sponsor
Dr Nityanand Tripathi
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Dr Nityanand Tripathi

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient is \= 18 and \= 40 years of age and going for PCI of the culprit lesion (more than 90 % diameter stenosis)
  • 2\. At least \=1 de novo lesions in a native coronary segment with a visually estimated diameter stenosis between \= 40 % and \< 90%
  • 3\. Patient has documented ACS (unstable angina, NSTEMI or STEMI within the previous 72 hours)
  • 4\. Patient demonstrates a left ventricular ejection fraction (LVEF) of \= 40% as measured prior to enrolment
  • 5\. Patient understands and agrees to comply with all specified study requirements and provides written Informed Consent to this effect

Exclusion Criteria

  • 1\) Patients with a medical condition that limits the life expectancy to 1 years or less
  • 2\) Patients scheduled to undergo surgery within 3 months that requires interruption of DAPT
  • 3\) Women who are pregnant or planning to be pregnant
  • 4\) Patients with allergy to contrast agents
  • 5\) Patients with coronary artery occlusion occurring at a site where a stent has already been placed or in whom observation by OCT is considered difficult
  • 6\) Patients in shock
  • 7\) Patients with a history of adverse reactions to aspirin, clopidogrel, or prasugrel
  • 8\) Patients who are ineligible for the study in the opinion of the investigator
  • 9\) Patients in whom follow\-up at 12 months after the index procedure is considered difficult
  • 10\) Patients with renal failure with a serum creatinine level of 2\.0 mg/dL or more at presentation (non\-HD patients)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A prospective, single-centre study to investigate the role of Optical Coherence Tomography and fractional flow reserve for post coronary angioplasty stent optimisatioHealth Condition 1: I208- Other forms of angina pectoris
CTRI/2021/04/032543PGIMER
Active, not recruiting
Phase 1
Study to investigate the performance of a newly developed patch insulin pump in patients with type 2 diabetesType 2 diabetes mellitusMedDRA version: 17.1Level: PTClassification code 10053247Term: Insulin-requiring type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2014-004078-40-ATCeQur Corp.
Completed
Not Applicable
A single-center, single-blind study to investigate skin response to sub-therapeutic doses of taspoglutide in GLP-1 analogue naive healthy volunteers
NL-OMON34382Hoffmann-La Roche6
Completed
Not Applicable
The effect of dietary rapeseed (canola) versus olive oil supplementation on serum lipids, liver enzymes and postprandial inflammatory responses in adipose tissue in obese men.ObesityNutritional, Metabolic, Endocrine
ISRCTN22073289The Union for the Promotion of Oil and Protein Plants e.V. (Union zur Foerderung von Oel- und Proteinpflanzen e.V) (Germany)20
Completed
Not Applicable
A single center, randomized study investigating the safety, tolerability, and pharmacokinetics of AZ-009 (Staccato apomorphine) in healthy volunteers and the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZ-009 in subjects with established Parkinson*s Disease.Parkinson's diseaseParkinson's DiseasePD
NL-OMON48728Alexza Pharmaceuticals Inc.56